WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Moderator

Clare Bailey, MD, FRCOphth

Consultant Ophthalmologist
Director of the Retinal Research and Treatment Unit
Bristol Eye Hospital
Bristol, United Kingdom

Disclosures

Clare Bailey, MD, FRCOphth, has the following relevant financial relationships:
Consultant or advisor for: Alimera Sciences; Apellis Pharmaceuticals, Inc.; Bayer; Boehringer-Ingelheim; Janssen; Novartis; Roche
Speaker or member of speakers bureau for: Bayer; Roche
Research funding from: Bayer; Gyroscope; Roche

Faculty

David Brown, MD

Professor of Ophthalmology
Baylor College of Medicine
Director of Research
Retina Consultants of Houston
Houston, Texas, United States

Disclosures

David Brown, MD, has the following relevant financial relationships:
Consultant or advisor for : Adverum Biotechnologies Inc.; AGTC; Alexion Pharmaceuticals, Inc; Annexon, Inc.; Apellis Pharmaceuticals, Inc; Bayer UK; Biogen MA Inc.; Boehringer Ingelheim; Celltrion; Chengdu Kanghong Pharmaceutical; Clearside Biomedical Inc.; Coherus BioScience, Inc.; Gemini Therapeutics Inc.; Glaukos; Iveric Bio, Inc.; Kodiak Sciences Inc.; Lineage Cell Therapeutics; Medscape, LLC; Novartis Pharma AG; OPTOS PLC; Ray Therapeutics Inc.; Regeneron Pharmaceuticals, Inc; RetinAI Medical AG; Samsung Bioepis Co., Ltd.; Senju Pharmaceuticals Co., Ltd.; Smilebiotek Zhuhai Limited; Stealth BioTherapeutics Inc.; Verseon
Research funding from : Adverum; Alderya; Alexion Pharmaceuticals, Inc; Alkahest; Alimera; Amgen; Annexon, Inc.; Apellis Pharmaceuticals, Inc.; Aura; Bayer UK; Boehringer Ingelheim; Boston Image Reading Center; Clearside Biomedical, Inc.; Eyepoint; Gemini Therapeutics Inc; Genentech/Roche; Graybug; Gyroscope; Johns Hopkins; Ionis; Irenix; Iveric; Kodiak Sciences Inc; Lowery Medical Research Group; Lumithera; Nanoscope; NEI/NH; Neurotech; NGM; Novartis Pharma AG; Ocular Therapeutix; Ocuphire Pharma, Inc; OIRRC; ONS; Opthea; Opthotech; OPTOS; Oxurion; Oysterpoint; Regeneron; REGENXBIO; Roche; SamChunDang; Samsung; Sandoz; Santen; Senju Pharmaceuticals Co., Ltd.; Stealth BioTherapeutics Inc; Unity; Xbrane; Zeiss
Contracted researcher for : Adverum; Alderya; Alexion Pharmaceuticals; Alkahest; Alimera; Amgen; Annexon Inc.; Apellis Pharmaceuticals, Inc.; Aura; Bayer UK; Boston Image Reading Center; Boehringer Ingelheim; Clearside Biomedical, Inc.; Eyepoint; Gemini Therapeutics, Inc.; Genentech/Roche; Graybug; Gyroscope; Johns Hopkins; Ionis; Irenix; Iveric; Kodiak Sciences, Inc.; Lowery Medical Research Group; Lumithera; Nanoscope; NEI/NH; Neurotech; NGM; Novartis Pharma AG; Ocular Therapeutix; Ocuphire Pharma, Inc; OIRRC ONS; Opthea; Opthotech; OPTOS; Oxurion; Oysterpoint; Regeneron; REGENXBIO; Roche; SamChunDang; Samsung; Sandoz; Santen; Senju; Stealth BioTherapeutics, Inc.; Unity; Xbrane; Zeiss
Stock options from: Adverum; Clearside

Roxane Hillier, MBChB, FRCOphth

Consultant Ophthalmologist and Vitreoretinal Surgeon
Research Lead for Ophthalmology
Newcastle Eye Centre
Honorary Senior Clinical Lecturer
Newcastle University
Newcastle-upon-Tyne, United Kingdom

Disclosures

Roxane Hillier, FRCOphth, has the following relevant financial relationships:
Consultant or advisor for: Roche
Speaker or member of speakers bureau for: Roche

Nancy Holekamp, MD

Director of Retina Services
Pepose Vision Institute
St. Louis, Missouri, United States

Disclosures

Nancy Holekamp, MD, has the following relevant financial relationships:
Consultant or advisor for: Adverum; Allergan; Annexon, Inc.; Apellis Pharmaceuticals, Inc.; Bayer; Cardinal; Clearside Biosciences; EyePoint Pharmaceuticals; Gemini Therapeutics, Inc.; Genentech; Gyroscope; Katalyst Surgical; Nacuity; NGM; Notal Vision; Novartis; Ocuphire; Outlook Therapeutics; Regeneron; Thea Laboratoires; Stealth BioTherapeutics, Inc.
Speaker or member of speakers bureau for: Allergan; Genentech; Regeneron; Spark
Research funding from: Gemini Therapeutics, Inc.; Genentech; Gyroscope; Notal Vision
Patent beneficiary of: Katalyst Surgical (The Holekamp Drip Dropper)
Stock options from: Gemini Therapeutics, Inc.; Nacuity
Owns stock (publicly traded) in: Apellis; Gemini Therapeutics, Inc.

Laura Sararols Ramsay, MD

Chief, Retina Unit
Hospital General de Catalunya
Barcelona, Spain
Hospital General de Granollers
Granollers, Spain

Disclosures

Laura Sararols Ramsay, MD, has the following relevant financial relationships:
Consultant or advisor for: Bayer; Novartis; Roche
Speaker or member of speakers bureau for: Bayer; Novartis; Roche
Research funding from: Bayer; ISEE; Iveric; Kokidak; Novartis; Roche

Editor

Katherine Carpenter, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Katherine Carpenter, PhD, has the following relevant financial relationship
Advisor or consultant for: Eisai (former), GW Pharmaceuticals (former)

Compliance Reviewer

Lisa Simani, APRN, MS, ACNP

Associate Director, Accreditation and Compliance

Disclosures

Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer:

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

From Medscape Education

Expert Views: Using Surgical Approaches for Neovascular Age-Related Macular Degeneration in Practice

Authors: Clare Bailey, MD, FRCOphth; David Brown, MD; Roxane Hillier, MBChB, FRCOphth; Nancy Holekamp, MD; Laura Sararols Ramsay, MDFaculty and Disclosures

processing....

Posted: 30/12/2022

This activity is intended for an international audience of non-US ophthalmologists, other eye care professionals, and all physicians who care for patients with neovascular age-related macular degeneration (nAMD).

The goal of this activity is that learners will be better able to advise their patients with nAMD on surgical approaches and use those surgical approaches in clinical practice once they become available.

Upon completion of this activity, participants will be able to:

Have increased knowledge regarding the
- Emerging surgical techniques for use in patients with nAMD
- Surgical protocol for placing a port delivery system (PDS)
- Patient education after surgical interventions

Contents of This Activity

All sections of this activity are required for credit.

Introduction

Dr Bailey introduces the challenges, the approaches, and the topics for this program.
Clare Bailey, MD, FRCOphth

Data Update: Surgical Approaches in nAMD

Learn about the latest data on surgical implants and gene therapy.
Laura Sararols Ramsay, MD

Experience From the United Kingdom: Surgical Approaches to nAMD

Hear this surgeon's initial experience implanting the port delivery system and tips for successful surgery.
Roxane Hillier, FRCOphth

Experience From the United States: Surgical Approaches to nAMD

Two expert surgeons give their pearls and pitfalls for implanting the port delivery system, and show some other novel surgical approaches to deliver therapeutics to the retina.
David Brown, MD; Nancy Holekamp, MD

Patient Monitoring: Surgical Approaches for nAMD

Expert surgeons advise on patient monitoring
David Brown, MD; Nancy Holekamp, MD

Conclusions

Dr Bailey concludes this series by summarizing the key points
Clare Bailey, MD, FRCOphth

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 12

Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Faculty and Disclosures

Moderator

Clare Bailey, MD, FRCOphth

Faculty

David Brown, MD

Roxane Hillier, MBChB, FRCOphth

Nancy Holekamp, MD

Laura Sararols Ramsay, MD